Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 13, 2024, serves as a report of foreign private issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The document discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly limited to reporting a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the purchase of American Depositary Receipts (ADRs) by a board member.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future performance, risk factors, or contingencies. It includes a standard corporate description stating the company's purpose to defeat serious chronic diseases and its listing status on Nasdaq Copenhagen and the New York Stock Exchange.
Important Facts for Investors
- Transaction Type: Purchase of 1,300 Novo Nordisk ADRs.
- Insider Identity: Choi Lai Christina Law, Member of the Board of Directors.
- Transaction Date: November 12, 2024.
- Transaction Price: DKK 743.31 per ADR.
- Total Value: DKK 966,301.02.
- Exchange: New York Stock Exchange.